Investing.com - ProQR Therapeutics NV (NASDAQ: PRQR) reported fourth quarter EPS of €-0.106, €0.12 worse than the analyst estimate of €0.011. Revenue for the quarter came in at €15.47M versus the consensus estimate of €14.74M.
ProQR Therapeutics NV's stock price closed at €2.000. It is up 15.610% in the last 3 months and down -30.310% in the last 12 months.
ProQR Therapeutics NV saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See ProQR Therapeutics NV's stock price’s past reactions to earnings here.
According to InvestingPro, ProQR Therapeutics NV's Financial Health score is "good performance".
Check out ProQR Therapeutics NV's recent earnings performance, and ProQR Therapeutics NV's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar